Compare · NNNN vs ORKA
NNNN vs ORKA
Side-by-side comparison of Anbio Biotechnology (NNNN) and Oruka Therapeutics Inc. (ORKA): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both NNNN and ORKA operate in Biotechnology: In Vitro & In Vivo Diagnostic Substances (Health Care), so they compete in similar markets.
- NNNN is the larger of the two at $3.98B, about 1.1x ORKA ($3.78B).
- Over the past year, NNNN is up 307.3% and ORKA is up 640.2% - ORKA leads by 333.0 points.
- ORKA has been more active in the news (11 items in the past 4 weeks vs 8 for NNNN).
- ORKA has more recent analyst coverage (11 ratings vs 0 for NNNN).
PerformanceNNNN+307.26%ORKA+640.21%
2025-04-28+0.00%2026-04-27
- Company
- Anbio Biotechnology
- Oruka Therapeutics Inc.
- Price
- $27.49-1.10%
- $76.39+10.76%
- Market cap
- $3.98B
- $3.78B
- 1M return
- +14.95%
- +68.04%
- 1Y return
- +307.26%
- +640.21%
- Industry
- Biotechnology: In Vitro & In Vivo Diagnostic Substances
- Biotechnology: In Vitro & In Vivo Diagnostic Substances
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2025
- News (4w)
- 8
- 11
- Recent ratings
- 0
- 11
Latest NNNN
- SEC Form 6-K filed by Anbio Biotechnology
- Amendment: SEC Form 20-F/A filed by Anbio Biotechnology
- SEC Form 3 filed by new insider Song Suki
- SEC Form 3 filed by new insider Hartzler Nancy
- SEC Form 3 filed by new insider Lau Michael
- SEC Form 3 filed by new insider Tian Chris
- SEC Form 3 filed by new insider Xu Cany
- SEC Form 20-F filed by Anbio Biotechnology
- Anbio Biotechnology to Participate in KeyBanc Capital Markets Healthcare Forum
- SEC Form 6-K filed by Anbio Biotechnology
Latest ORKA
- SEC Form 424B5 filed by Oruka Therapeutics Inc.
- SEC Form 424B5 filed by Oruka Therapeutics Inc.
- Oruka Therapeutics Announces Proposed $500 Million Underwritten Public Offering
- Oruka Therapeutics Inc. filed SEC Form 8-K: Regulation FD Disclosure, Other Events, Financial Statements and Exhibits
- Oruka Therapeutics Announces Positive Week 16 Data for ORKA-001 from the Ongoing EVERLAST-A Phase 2a Trial in Moderate-to-Severe Plaque Psoriasis
- Oruka Therapeutics to Host Conference Call to Report Week 16 Data for ORKA-001 from the Ongoing EVERLAST-A Trial on April 27, 2026
- SEC Form 424B7 filed by Oruka Therapeutics Inc.
- SEC Form DEFA14A filed by Oruka Therapeutics Inc.
- SEC Form DEF 14A filed by Oruka Therapeutics Inc.
- SEC Form 4 filed by Goncalves Joana